Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB

BIOGEN INC (BIIB)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/20/2017 03/21/2017 03/22/2017 03/23/2017 03/24/2017 Date
274.8(c) 275.79(c) 277.87(c) 275.41(c) 274.82(c) Last
1 666 855 3 841 567 1 333 588 1 605 032 1 368 217 Volume
-0.47% +0.36% +0.75% -0.89% -0.21% Change
More quotes
Financials ($)
Sales 2017 11 281 M
EBIT 2017 6 076 M
Net income 2017 4 024 M
Finance 2017 41,4 M
Yield 2017 -
Sales 2018 11 975 M
EBIT 2018 6 441 M
Net income 2018 4 411 M
Finance 2018 1 940 M
Yield 2018 -
P/E ratio 2017 14,70
P/E ratio 2018 13,28
EV / Sales2017 5,26x
EV / Sales2018 4,79x
Capitalization 59 348 M
More Financials
Company
Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders.Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for... 
Sector
Pharmaceuticals
Calendar
04/27Earnings Release
More about the company
Surperformance© ratings of Biogen Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN INC
03/16 BIOGEN : Appoints Anirvan Ghosh Senior Vice President, Research and Early Develo..
03/01 BIOGEN : Biotech Stocks Under Scanner -- Immunomedics, Peregrine Pharma, Vericel..
02/28 BIOGEN : to Present at the Cowen & Company 37th Annual Health Care Conference
02/15 BIOGEN : to Present at the 2017 RBC Capital Markets Global Healthcare Conference
02/07 BIOGEN : to Present at the Leerink Partners 6th Annual Global Healthcare Confere..
02/02 BIOGEN INC : Spin off
02/01 BIOGEN : Completes Separation of Global Hemophilia Business, Bioverativ
01/26DJBIOGEN : Profit Skids, Revenue Grows Less Than Expected
01/26 BIOGEN : Reports 2016 Revenues of $11.4 Billion
01/23BIOGEN INC : annual earnings release
More news
Sector news : Biopharmaceuticals
09:25a Chinese drug approval boosts AstraZeneca's lung cancer hopes
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
More sector news : Biopharmaceuticals
4-Traders Strategies on BIOGEN INC 
2014Back on a stimulating support
2013The bullish trend is not over
More Strategies
Latest Tweets
01:18aWith Healthcare Now Off Trump's Agenda, It's Time To Dive Into The Sector $BI..
1
01:12aWith Healthcare Now Off Trump's Agenda, It's Time To Dive Into The Sector
2
03/25Biogen upgraded by Vetr Inc. to strong-buy. $310.17 PT.  
03/24Who are your #biotech heroes? Stelios Papadopoulos tells us his. #blog
6
03/23Shorts: $ARRS $BIIB $HCA $MYL $PSX 
More tweets
Qtime:126
News from SeekingAlpha
03/26 With Healthcare Now Off Trump's Agenda, It's Time To Dive Into The Sector
03/22 Court Victory Benefits Biogen And Its Tecfidera Rival Alike
03/21 Biogen victory makes company more attractive M&A target - RBC
03/21 Biotechs under pressure after Trump (again) decries high drug prices
03/21 Biogen up 1% on favorable patent decision
Advertisement
Chart BIOGEN INC
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 317 $
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC5.16%59 348
CSL LIMITED23.00%42 869
ALEXION PHARMACEUTICAL..-2.53%26 787
BIOMARIN PHARMACEUTICA..5.47%15 103
GRIFOLS SA17.32%14 943
CHONGQING ZHIFEI BIOLO..--.--%4 160
More Results